Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Sanofi and Kymera sign protein degrader deal

by Lisa M. Jarvis
July 11, 2020 | A version of this story appeared in Volume 98, Issue 27

 

Sanofi will pay Kymera Therapeutics $150 million up front to develop therapies that degrade IRAK4, a protein implicated in immune-inflammatory diseases. Several other companies are developing compounds that inhibit IRAK4, but Kymera’s drug candidates break down rather than block the protein. Kymera, which will be responsible for Phase I studies before passing the baton to Sanofi, hopes to put its protein degrader into the clinic in the first half of 2021. That could make it the first protein degrader to enter human studies outside the field of oncology.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.